This study is to test the safety of a new drug called MBX 2109 for patients with hypoparathyroidism – a condition where the body doesn't make enough parathyroid hormone, affecting calcium levels. MBX 2109 aims to keep calcium levels normal without extra vitamin D or calcium supplements. Patients will get the drug once a week.

To join, you must be an adult and have had hypoparathyroidism for at least 26 weeks. You can't join if you have other health conditions affecting calcium or are using certain other medications.

• The study involves regular check-ups and tests.
• You may need to stop certain medications before joining.
• Participants will receive compensation for their time and travel.

If eligible, you'll need to sign a consent form, agreeing to follow study rules. Participation is voluntary and you can leave at any time. This study helps us learn how well MBX 2109 works and its side effects.